GRTS - It's Time To Buy Gritstone Oncology As First Vaccine Treated Colorectal Cancer Patient Nears RECIST Confirmed Response
I first covered the immune-oncology company Gritstone Oncology (GRTS) following the GRANITE phase 1 results which illustrated both safety and clinical benefit in a very small set of 5 heavily pre-treated patients representing different tumor types and varying dose levels. As a reminder their flagship product GRANITE is a personalized neoantigen vaccine which works by inducing a CD8+ T cell response to attack a tumor. A cancer vaccine tailored specifically to a patient’s neoantigen profile is about as cutting-edge as you can get and the GRANITE product is at the forefront. The stock